Article | Published:

A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo

Acta Pharmacologica Sinica | Download Citation

Subjects

Abstract

Liver fibrosis is excessive accumulation of extracellular matrix proteins that results from various chronic liver diseases. Hepatic stellate cells (HSCs) play an essential role in the pathogenesis of liver fibrosis. Danggui Buxue Tang (DBT) is a classic formula of Chinese traditional medicine. We previously showed that DBT could ameliorate liver fibrosis in rats. However, the bioactive components of DBT in the treatment of liver fibrosis remain unknown. In this study we evaluated 14 ingredients from DBT in human hepatic stellate cell line LX-2, and found that astragaloside I (A), levistilide A (L) and calycosin (C) produced synergistic proliferation inhibition on LX-2 cells and TGF-β1-activated LX-2 cells. Thus, we prepared a mixture of them, and named this combination as ALC formula. Using high-content screening and Western blot assay we revealed that the ALC formula significantly reduced the expression of α-SMA and collagen I in LX-2 cells. The in vivo anti-fibrosis effects of ALC formula were evaluated in a liver fibrosis model in C57BL/6 mice established through injection of dimethylnitrosamine (DMN 2 mg/kg, ip) for 4 weeks. In the third week, the nice were injected with ALC formula (astragaloside I 44.21 mg/kg per day, levistilide A 6 mg/kg per day and calycosin 3.45 mg/kg per day; ip) or sorafenib, a positive control drug (6 mg/kg per day, ip) for 2 weeks. We found that administration of the ALC formula markedly decreased collagen deposition, hydroxyproline (Hyp) content and α-SMA expression levels in the liver tissues compared to the model mice. In conclusion, the present study demonstrates for the first time that astragaloside I, levistilide A and calycosin may be the 3 main bioactive components in DBT; their combination exerts anti-liver fibrosis effects in vitro and in vivo.

  • Subscribe to Acta Pharmacologica Sinica for full access:

    $576

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , . Pathobiology of liver fibrosis: a translational success story. Gut 2015; 64: 830–41.

  2. 2.

    , . Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028–40.

  3. 3.

    , , , , . High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protocols 2015; 10: 305–15.

  4. 4.

    , , , , , , et al. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. Chem Biol Interact 2014; 224: 58–67.

  5. 5.

    , . Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype. J Hepatol 2014; 61: 166–68.

  6. 6.

    , , , , , , et al. The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis. Evid Based Complement Alternat Med 2012; 224: 58–67.

  7. 7.

    , , , , , . Effects of Danggui Buxue Decoction on lipid peroxidation and MMP-2/9 activities of fibrotic liver in rats. Chin J Integr Med 2009; 15: 435–41.

  8. 8.

    , , , , , , et al. Evaluating the bone tissue regeneration capability of the Chinese herbal decoction Danggui Buxue Tang from a molecular biology perspective. Biomed Res Int 2014; 2014: 853234.

  9. 9.

    , , , , , . Functions of Danggui Buxue Tang, a Chinese Herbal Decoction containing Astragali Radix and Angelicae Sinensis Radix, in uterus and liver are both estrogen receptor-dependent and -independent. Evid Based Complement Alternat Med 2014; 2014: 438531.

  10. 10.

    , , , , , , et al. Calycosin orchestrates the functions of Danggui Buxue Tang, a Chinese herbal decoction composing of Astragali Radix and Angelica Sinensis Radix: An evaluation by using calycosin-knock out herbal extract. J Ethnopharmacol 2015; 168: 150–7.

  11. 11.

    , , , , , , et al. Total glucosides of Danggui Buxue Tang attenuate BLM-induced pulmonary fibrosis via regulating oxidative stress by inhibiting NOX4. Oxid Med Cell Longev 2015; 2015: 645814.

  12. 12.

    , , . Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus. Exp Ther Med 2016; 11: 2477–83.

  13. 13.

    , , , , , . Simultaneous determination of bioactive constituents in Danggui Buxue Tang for quality control by HPLC coupled with a diode array detector, an evaporative light scattering detector and mass spectrometry. Anal Bioanal Chem 2007; 389: 571–80.

  14. 14.

    , , , , , , et al. Chemical and biological assessment of Angelica herbal decoction: comparison of different preparations during historical applications. Phytomedicine 2012; 19: 1042–8.

  15. 15.

    , , , , . Liquid chromatographic–electrospray mass spectrometric study of the phthalides of Angelica sinensis and chemical changes of Z-ligustilide. J Chromatogr A 1998; 810: 71–9.

  16. 16.

    , , , , , , et al. Identification and quantification of 13 components in Angelica sinensis (Danggui) by gas chromatography–mass spectrometry coupled with pressurized liquid extraction. Anal Chim Acta 2004; 526: 131–7.

  17. 17.

    , , , , , , et al. Chemical and biological assessment of a Chinese herbal decoction containing Radix Astragali and Radix Angelicae Sinensis: determination of drug ratio in having optimized properties. J Agric Food Chem 2006; 54: 2767–74.

  18. 18.

    , . Chemical composition and inhibitory effect on hepatic fibrosis of Danggui Buxue Decoction. Fitoterapia 2010; 81: 793–8.

  19. 19.

    , , , , . Quality control of Danggui Buxue Tang, a Traditional Chinese Medicine Decoction, by 1H-NMR metabolic profiling. Evid Based Complement Alternat Med 2014; 2014: 567893.

  20. 20.

    , , , , , , et al. Pharmacokinetic comparison of seven major bio-active components in normal and blood deficiency rats after oral administration of Danggui Buxue decoction by UPLC-TQ/MS. J Ethnopharmacol 2014; 153: 169–77.

  21. 21.

    , , , , , , et al. Chemical profile analysis and comparison of two versions of the classic TCM formula Danggui Buxue Tang by HPLC-DAD-ESI-IT-TOF-MSn. Molecules 2014; 19: 5650–73.

  22. 22.

    , , . , . , et al. Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol 2014; 63: 73–81.

  23. 23.

    , , , . , , et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 2008; 105: 4826–31.

  24. 24.

    . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440–6.

  25. 25.

    . Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity—Letter. Cancer Res 2011; 71: 2793–93.

  26. 26.

    , , . Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells. Phytomedicine 2012; 19: 1288–97.

  27. 27.

    , , . A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112: 70–5.

  28. 28.

    , . Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76–99.

  29. 29.

    , . Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006; 21 (s3).

  30. 30.

    , , . Mechanism of liver fibrosis. Clin Chim Acta 2006; 364: 33–60.

  31. 31.

    . Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. World J Gastroenterol 2014; 20: 7260.

  32. 32.

    , . Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci 2015; 22: 512–8.

  33. 33.

    , , , , , , et al. Hepatoprotective effect of juglone on dimethylnitrosamine-induced liver fibrosis and its effect on hepatic antioxidant defence and the expression levels of α-SMA and collagen III. Mol Med Rep 2015; 12: 4095–102.

  34. 34.

    , , , , , . New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132–44.

  35. 35.

    , , , , , , et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011; 54: 573–85.

  36. 36.

    , , , , , , et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib. J Autoimm 2013; 46: 25–34.

  37. 37.

    , , , , , , et al. Antifibrosis effects of total glucosides of Danggui–Buxue–Tang in a rat model of bleomycin-induced pulmonary fibrosis. J Ethnopharmacol 2011; 136: 21–6.

  38. 38.

    . , , , , , et al. Total glucosides of Danggui Buxue Tang attenuates bleomycin-induced pulmonary fibrosis via inhibition of extracellular matrix remodelling. J Pharm Pharmacol 2012; 64: 811–20.

  39. 39.

    , , , . Antifibrotic effect of the Chinese herbs Modified Danggui Buxue Decoction on adriamycin-induced nephropathy in rats. Chin J Integr Med 2012; 18: 591–8.

  40. 40.

    , , , , , . Strategy for analysis and screening of bioactive compounds in traditional Chinese medicines. J Chromatogr B 2004; 812: 71–84.

  41. 41.

    , , , . Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scandinavian J Gastroenterol 2005; 40: 867–72.

Download references

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No 81402515 and 81473404).

We thank Dr Jing LYU for providing the methods and other helps.

Author information

Affiliations

  1. Institute of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

    • Tao Guo
    • , Zu-long Liu
    • , Qiang Zhao
    • , Zhi-min Zhao
    •  & Cheng-hai Liu
  2. Shanghai Clinical Key Laboratory of Traditional Chinese Medicine, Shanghai 201203, China

    • Zhi-min Zhao
    •  & Cheng-hai Liu
  3. Department of Gastroentology, Hospital No.455 of the PLA, Shanghai 200052, China

    • Tao Guo

Authors

  1. Search for Tao Guo in:

  2. Search for Zu-long Liu in:

  3. Search for Qiang Zhao in:

  4. Search for Zhi-min Zhao in:

  5. Search for Cheng-hai Liu in:

Corresponding authors

Correspondence to Zu-long Liu or Cheng-hai Liu.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/aps.2017.175

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.